Kura Oncology, Inc. (NASDAQ:KURA) SVP Sells $38,948.63 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Kura Oncology Price Performance

KURA opened at $8.03 on Friday. The firm has a market cap of $624.41 million, a price-to-earnings ratio of -3.40 and a beta of 0.81. Kura Oncology, Inc. has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company’s 50-day moving average price is $9.02 and its 200 day moving average price is $15.58. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. As a group, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. HC Wainwright increased their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, November 21st. Jefferies Financial Group lowered their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. UBS Group began coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Institutional Trading of Kura Oncology

A number of large investors have recently added to or reduced their stakes in KURA. Hsbc Holdings PLC boosted its holdings in Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after buying an additional 2,167 shares in the last quarter. Marshall Wace LLP bought a new stake in Kura Oncology during the second quarter worth approximately $541,000. AQR Capital Management LLC boosted its holdings in Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after buying an additional 58,422 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after buying an additional 1,976 shares in the last quarter. Finally, Quarry LP bought a new stake in Kura Oncology during the second quarter worth approximately $196,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.